We previously reported that glycoxidized low-density lipoprotein (glycoxidized LDL) enhanced monocyte chemoattractant protein-1 (MCP-1) mRNA expression through activation of nuclear factor-kappaB (NF-kappaB). Here we investigated the effects of dilazep, an anti-platelet agent, and fenofibric acid, an active metabolite of fenofibrate, on glycoxidized low-density lipoprotein-(LDL)-enhanced MCP-1 mRNA expression. Both 10 microg/ml dilazep and 100 microM fenofibric acid abrogated MCP-1 mRNA expression. ZM241385, an A2a adenosine receptor antagonist, partially inhibited the suppressive effect of dilazep. NF-kappaB activity was also suppressed by 1 microg/ml dilazep and 10 microM fenofibric acid. The antioxidative activity of these drugs on glycation to native LDL or oxidation to glycated LDL was measured using lipid peroxidation and lyso-phosphatidylcholine contents in LDL. Dilazep but not fenofibric acid exhibited antioxidative activity. Although the mechanisms of anti-atherogenic effects of the two drugs on glycoxidized LDL are different, both dilazep and fenofibric acid could potentially prevent atherosclerosis in diabetes mellitus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0014-2999(03)02109-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Significantly improving the solubility and anti-inflammatory activity of fenofibric acid with native and methyl-substituted beta-cyclodextrins via complexation.
Sci Rep
January 2025
School of Chemical Engineering, Yeungnam University, Gyeongsan, 38541, Republic of Korea.
The solubility of commonly used anti-inflammatory drugs has become a significant concern in contemporary medicine. Furthermore, inflammatory arthritis stands out as the most prevalent chronic inflammatory disease globally. The disease's pathology is characterized by heightened inflammation and oxidative stress, culminating in chronic pain and the loss of joint functionality.
View Article and Find Full Text PDFAdministration time modify the anxiolytic and antidepressant effects of inulin via gut-brain axis.
Int J Biol Macromol
February 2025
College of Food Science and Technology, Key Laboratory of Environment Correlative Food Science, Huazhong Agricultural University, Wuhan 430070, China.. Electronic address:
An imbalance in the microbiota-gut-brain axis exerts an essential effect on the pathophysiology of depressive and anxiety disorders. Our previous research revealed that the timing of inulin administration altered its effects on chronic unpredictable mild stress (CUMS)-induced anxiety and depression. However, it is still unclear if the gut-brain axis is primarily responsible for these effects.
View Article and Find Full Text PDFA facile synthesis of 2-(4-((4-chlorophenyl)(hydroxy)methyl) phenoxy)-2-methylpropanoic acid: Metabolite of anti-hyperlipidemic drug Fenofibrate.
Results Chem
January 2024
Department of Chemistry, Youngstown State University, One University Plaza, Youngstown, OH, USA.
Synthesis and characterization of drug metabolites has emerged as an important area of research in consideration to the significant contribution of studies on metabolites in drug research. The present work comprises synthesis of 2-(4-((4-chlorophenyl)(hydroxy)methyl) phenoxy)-2-methylpropanoic acid, a metabolite of anti-hyperlipidemic drug fenofibrate. The desired compound was prepared by two different synthetic routes.
View Article and Find Full Text PDFRepositioning of the Antihyperlipidemic Drug Fenofibrate for the Management of Infections.
Microorganisms
February 2024
Unit of Microbiology, Department of Basic Health Sciences, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili (IISPV), University Rovira i Virgili, 43201 Reus, Spain.
Fenofibrate is a fibric acid derivative used as an antihyperlipidemic drug in humans. Its active metabolite, fenofibric acid, acts as an agonist to the peroxisome proliferator-activated receptor alpha (PPAR-α), a transcription factor involved in different metabolic pathways. Some studies have reported the potential protective role of this drug in cell lines and in vivo models against bacterial and viral infections.
View Article and Find Full Text PDFDifferent Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease.
Biomedicines
March 2024
Department of Health Chemistry, Showa Pharmaceutical University, Machida 194-8543, Tokyo, Japan.
Article Synopsis
- The text discusses three types of peroxisome proliferator-activated receptors (PPARs) - PPARα, PPAR(ß/)δ, and PPARγ - and their role in gene transcription regulation through interactions with retinoid X receptors (RXRs)
- It highlights how ligand-bound PPAR/RXR complexes recruit specific coactivator proteins to gene regulatory locations, impacting gene expression, but emphasizes that each PPAR can interact with only one coactivator at a time via a specific motif (LXXLL)
- The study investigates the recruitment of various coactivators by different PPAR agonists intended for treating nonalcoholic fatty liver disease, finding that the efficacy and potency of co
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!